佐力药业：近年来随着公司主要产品逐步放量销售，业绩进入上行期

Core Viewpoint - Zhaoli Pharmaceutical (300181) is experiencing an upward trend in performance due to the gradual increase in sales of its main products and has initiated capacity expansion projects to meet market demand [1] Group 1 - The company has started fundraising projects in 2022 to expand production capacity [1] - The company aims to balance steady operations, performance growth, and shareholder returns in its future strategies [1] - The company is committed to actively rewarding investors as part of its operational strategy [1]